Want to see IN:ALIVUS full AI Analyst Report?

Glenmark Life Sciences Limited (ALIVUS) Price & Analysis

5 Followers

ALIVUS Stock Chart & Stats

₹920.80

-₹16.95(-1.62%)

At close: Jan 09 4:00 PM EST

₹920.80

-₹16.95(-1.62%)

Day’s Range― - ―

52-Week Range₹830.00 - ₹1,193.30

Previous CloseN/A

VolumeN/A

Average Volume (3M)7.13K

Market Cap

₹138.32B

Enterprise Value₹129.55B

Total Cash (Recent Filing)₹6.53B

Total Debt (Recent Filing)₹1.13B

Price to Earnings (P/E)24.9

Beta0.81

Next Earnings

Jul 31, 2026

EPS Estimate

12.1

Next Dividend Ex-DateN/A

Dividend Yield0.56%

Share Statistics

EPS (TTM)22.17

Shares Outstanding122,739,450

10 Day Avg. Volume3,315

30 Day Avg. Volume7,125

Financial Highlights & Ratios

PEG Ratio1.32

Price to Book (P/B)3.59

Price to Sales (P/S)4.69

P/FCF Ratio46.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)52

Revenue Forecast (FY)₹27.95B

Bulls Say, Bears Say

Bulls Say

High ProfitabilitySustained high margins across gross, EBIT and net lines reflect durable manufacturing efficiency and pricing power in APIs. That margin profile supports long-term cash earnings, funds reinvestment and withstands moderate volume swings across therapeutic segments.

Strong Revenue AccelerationA material revenue jump in FY2026 signals successful commercialization or volume growth across product lines. If driven by scaleable API wins and repeat contracts, this supports sustained top-line momentum and better fixed-cost absorption over the medium term.

Very Low Leverage & Solid ROEExtremely low leverage combined with ~17% ROE provides strong financial resilience and flexibility to invest or fund volatility without heavy refinancing risk. This capital structure supports durable operations and optionality for capex or strategic moves.

Bears Say

Weak Cash ConversionFree cash flow materially trails reported earnings, implying working capital or capex needs absorb cash. Persistently low cash conversion limits distributable cash, reduces buffer for downturns and constrains debt capacity or M&A funding without equity.

Margin VolatilityNotable margin variability versus prior peaks suggests exposure to product mix shifts, pricing pressure or input cost swings. Such structural volatility can compress earnings predictability and makes long‑term margin sustainability more uncertain.

Past High Leverage EpisodeHistorical spike in leverage shows the balance sheet can move materially under stress or growth funding. While currently conservative, the precedent increases governance focus needed to avoid recurrence during cyclical slowdowns or aggressive expansion.

Glenmark Life Sciences Limited News

Alivus Life Sciences Schedules Analyst and Institutional Investor Meetings

An announcement from Glenmark Life Sciences Limited ( ($IN:ALIVUS) ) is now available. Alivus Life Sciences Limited has...

4M ago

Alivus says Dahej fire impact limited, production to restart in March

Glenmark Life Sciences Limited ( ($IN:ALIVUS) ) has issued an update. Alivus Life Sciences has clarified the operational...

5M ago

ALIVUS FAQ

What was Glenmark Life Sciences Limited’s price range in the past 12 months?

Glenmark Life Sciences Limited lowest stock price was ₹830.00 and its highest was ₹1193.30 in the past 12 months.

What is Glenmark Life Sciences Limited’s market cap?

Glenmark Life Sciences Limited’s market cap is ₹138.32B.

When is Glenmark Life Sciences Limited’s upcoming earnings report date?

Glenmark Life Sciences Limited’s upcoming earnings report date is Jul 31, 2026 which is in 20 days.

How were Glenmark Life Sciences Limited’s earnings last quarter?

Glenmark Life Sciences Limited released its earnings results on May 14, 2026. The company reported ₹14.1 earnings per share for the quarter, beating the consensus estimate of ₹11.7 by ₹2.4.

Is Glenmark Life Sciences Limited overvalued?

According to Wall Street analysts Glenmark Life Sciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Glenmark Life Sciences Limited pay dividends?

Glenmark Life Sciences Limited pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.56%. See more information on Glenmark Life Sciences Limited dividends here

What is Glenmark Life Sciences Limited’s EPS estimate?

Glenmark Life Sciences Limited’s EPS estimate is 12.1.

How many shares outstanding does Glenmark Life Sciences Limited have?

Glenmark Life Sciences Limited has 122,739,450 shares outstanding.

What happened to Glenmark Life Sciences Limited’s price movement after its last earnings report?

Glenmark Life Sciences Limited reported an EPS of ₹14.1 in its last earnings report, beating expectations of ₹11.7. Following the earnings report the stock price went down -1.747%.

Which hedge fund is a major shareholder of Glenmark Life Sciences Limited?

Currently, no hedge funds are holding shares in IN:ALIVUS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Glenmark Life Sciences Limited

Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, production, and global commercialization of active pharmaceutical ingredients (APIs). Its market footprint spans India, Japan, Europe, and both North and Latin America, supported by substantial export operations. Alivus Life Sciences provides an extensive catalog of APIs, including olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib. These ingredients are utilized across a diverse array of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppression, respiratory and ophthalmological conditions, urology, and anti-infectives. Additionally, the company extends its expertise by offering contract development and manufacturing services (CDMO) to numerous multinational corporations and specialty pharmaceutical enterprises.